Infant Pain ManagementNCT07286721
White Noise and Buzzy for Reducing Pain During Infant Vaccination
A study of Infant Pain Management, run by Istanbul Arel University at 1 site in Turkey (Türkiye).
Trial summary
This randomized controlled trial aims to evaluate the effectiveness of two non-pharmacological methods-white noise and the Buzzy device-in reducing pain experienced by infants during routine vaccination. Read more about this study
- Who is it for?
- Ages 2 to 6 monthsHealthy volunteers can take part
- Conditions the study is for
- Infant Pain Management
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 108 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 25 Sep 2025to 20 May 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 6 months
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Infants aged 2 to 6 months
- Receiving routine hexavalent vaccination
- Born at term (≥37 weeks gestation)
- Medically stable at the time of vaccination
- Parent or legal guardian able to provide written informed consent Exclusion Criteria
- Infants with neurological disorders or developmental delay
Show all 11Show fewer
- Use of analgesic, antipyretic, or sedative medications within 24 hours prior to vaccination
- Skin conditions or contraindications at the injection site
- Hearing impairment that may affect response to white noise
- History of adverse reactions to vaccination
- Preterm infants (<37 weeks gestation)
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Büyükçekmece Central Family Health Center
Istanbul, Istanbul, 34500
About this study
Official title: The Effect of White Noise and Buzzy Use on Pain During Infant Vaccination: A Randomized Controlled Trial
This randomized controlled trial aims to evaluate the effectiveness of two non-pharmacological methods-white noise and the Buzzy device-in reducing pain experienced by infants during routine vaccination. Infants are known to feel pain, and untreated or poorly managed pain during early life may lead to negative short- and long-term outcomes. Therefore, identifying effective, safe, and easy-to-apply pain-reducing strategies is essential for improving infant comfort and supporting evidence-based nursing practices.
Read the detailed description
Pain during routine vaccination is a common clinical challenge in infancy. Although short in duration, procedural pain can cause significant distress for infants and caregivers, and repeated painful experiences during early life have been associated with negative physiological, behavioral, and neurodevelopmental outcomes. Current guidelines from pediatric and neonatal organizations emphasize the importance of minimizing pain through safe, effective, and feasible strategies. Non-pharmacological methods such as white noise and vibration-cold devices (e.g., Buzzy) are increasingly recommended because they are simple, inexpensive, and easily integrated into routine clinical workflows. However, there is limited evidence comparing the effectiveness of these two methods specifically during infant vaccination.
This study is designed as a single-center, randomized controlled, experimental trial aimed at evaluating and comparing the effects of white noise and the Buzzy device on pain experienced by infants during vaccination. The study will be conducted at the Büyükçekmece Central Family Health Center in Istanbul, Türkiye, between October 2025 and October 2026. The target population includes healthy infants aged 0 to 6 months who are scheduled to receive the routine hexavalent vaccine (diphtheria, acellular pertussis, tetanus, inactivated polio, Haemophilus influenzae type B, and hepatitis B).
A total of 108 infants will be included based on a priori power analysis performed using G*Power software, assuming an alpha level of 0.05, a power of 95%, and an anticipated large effect size. To account for potential dropout or exclusions, 36 infants will be assigned to each of the three study groups: (1) White Noise Group, (2) Buzzy Device Group, and (3) Control Group. Randomization will be conducted by an independent statistician using stratified randomization based on infant age (2, 4, or 6 months) and sex to ensure balanced distribution across groups. The study will use a single-blind design in which the observer assessing pain scores is blinded to group assignment.
In the White Noise Group, infants will listen to white noise beginning approximately 1 to 2 minutes before the vaccination and continuing throughout the procedure. The device will be placed safely within hearing distance of the infant. In the Buzzy Group, the Buzzy device-providing combined vibration and cold stimulation-will be applied approximately 3 cm above the injection site starting 60 seconds before the injection and will remain active until the end of the vaccination. In the Control Group, infants will receive the standard vaccination procedure without additional intervention. All vaccinations will be performed by the same trained nurse to ensure procedural consistency. A parent will remain present for the infant's comfort and to assist in observing behavioral cues.
Pain will be evaluated using the validated FLACC Pain Assessment Scale (Face, Legs, Activity, Cry, Consolability), a widely used behavioral tool suitable for infants and young children. During the vaccination, pain scores will be independently assessed by both a blinded observer (trained research nurse) and the parent. The total FLACC score ranges from 0 (no pain) to 10 (severe pain). Higher scores indicate greater pain. Sociodemographic data for infants and parents will also be collected using a structured introductory information form developed from relevant literature.
Data analysis will be performed using SPSS software. Normality of continuous variables will be assessed using the Kolmogorov-Smirnov test. Depending on the distribution, appropriate parametric or non-parametric tests will be applied. Between-group comparisons for FLACC scores will be conducted using ANOVA or the Kruskal-Wallis test, with post hoc analyses performed where necessary. Descriptive statistics (mean, median, standard deviation, and percentages) will be used to summarize sample characteristics. A significance level of p < 0.05 will be used for all statistical tests.
The primary objective of this study is to determine whether white noise or the Buzzy device is more effective in reducing pain during infant vaccination compared with standard care. Secondary objectives include comparing the relative effectiveness of the two methods against each other and evaluating factors that may influence pain perception, such as infant age and sex. By generating evidence on the comparative effectiveness of these widely available non-pharmacological interventions, this study aims to support the development of best practices for infant pain management in primary care settings.
The findings may inform clinical guidelines, enhance nurse-led pain management strategies, and contribute to the broader adoption of evidence-based, non-pharmacological methods in pediatric care. If shown to be effective, these techniques may be recommended for routine use during infant vaccinations to improve comfort, reduce distress, and support family-centered care. The study also seeks to raise awareness among healthcare providers and caregivers regarding simple, safe, and practical ways to reduce procedural pain in infants.
- Conditions
- Infant Pain Management
- Being tested
- Standard Care (in control arm)
- Keywords
- Infant pain, White noise, Buzzy, Vaccination, Nursing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard Care (in control arm)Other
White noise will be played 1-2 minutes before vaccination and continued throughout the procedure. The device will be placed within safe hearing distance of the infant. This auditory distraction method is intended to reduce procedural pain. No physical stimulation will be applied.
The Buzzy device will be placed about 3 cm above the injection site 60 seconds before vaccination and kept active until the procedure ends. The device provides vibration and cold stimulation to decrease pain by activating competing sensory pathways.
Infants in the control arm will receive routine vaccination with no additional intervention. No white noise, vibration, or cold stimulation will be used. Pain will be assessed according to standard observation procedures.
| Study group | Role | What they receive |
|---|---|---|
| White Noise Group | Experimental | Infants in this group will listen to white noise beginning approximately 1-2 minutes before the vaccination and continuing throughout the injection procedure. The white noise device will be placed safely within hearing distance of the infant. Pain will be assessed using the FLACC Pain Assessment Scale by a blinded observer and a parent. Receives: Other: Standard Care (in control arm) |
| Buzzy Device Group | Experimental | Infants in this group will receive vibration and cold stimulation using the Buzzy device. The device will be placed about 3 cm above the injection site 60 seconds before vaccination and will remain active until the procedure is completed. Pain will be assessed using the FLACC Pain Assessment Scale by a blinded observer and a parent. Receives: Other: Standard Care (in control arm) |
| Control Group | Experimental | Infants in this group will receive routine vaccination following standard clinical practice with no additional non-pharmacological intervention. Pain will be assessed using the FLACC Pain Assessment Scale by a blinded observer and a parent. Receives: Other: Standard Care (in control arm) |
What is being measured
The primary outcome is the main question the study is designed to answer.
FLACC Pain Score During Vaccination
Pain during vaccination will be assessed using the FLACC Pain Assessment Scale (Face, Legs, Activity, Cry, Consolability). Scores range from 0 to 10, with higher scores indicating greater pain. Pain will be independently evaluated for each infant by a blinded observer and a parent.
Measured: Periprocedural (during vaccination)
Secondary outcomes (1)
Agreement Between Parent and Observer FLACC Pain Scores
The level of agreement between FLACC pain scores assessed by a blinded observer and a parent during infant vaccination will be evaluated. Inter-rater agreement will be analyzed to assess the reliability of observational pain assessment across the three study groups.
Measured: Immediately after vaccination
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2025
- Study start25 Sep 2025
- Primary completion1 Apr 2026
- Study completion20 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Infant Pain ManagementStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 108 participants (actual)
Sponsor and investigators
- Lead sponsor
- Istanbul Arel University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Burcu SELVI CALISKAN, Istanbul Arel University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07286721
- Sponsor's protocol ID
- 2025/21
- Status last verified
- May 2026
- First submitted
- 3 Dec 2025
- Last updated
- 2 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to ethical and confidentiality considerations.
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of White Noise and Buzzy Use on Pain During Infant Vaccination: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07286721
- Acronym / sponsor ID
- 2025/21
- Conditions
- Infant Pain Management
- Keywords
- Infant pain, White noise, Buzzy, Vaccination, Nursing
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 108 participants (actual)
- Lead sponsor
- Istanbul Arel UniversityUniversity, hospital or other
- Study start
- 25 Sep 2025 (actual)
- Primary completion
- 1 Apr 2026 (actual)
- Study completion
- 20 May 2026 (actual)
- First posted
- 16 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled trial aims to evaluate the effectiveness of two non-pharmacological methods-white noise and the Buzzy device-in reducing pain experienced by infants during routine vaccination. Infants are known to feel pain, and untreated or poorly managed pain during early life may lead to negative short- and long-term outcomes. Therefore, identifying effective, safe, and easy-to-apply pain-reducing strategies is essential for improving infant comfort and supporting evidence-based nursing practices.
Detailed description
Pain during routine vaccination is a common clinical challenge in infancy. Although short in duration, procedural pain can cause significant distress for infants and caregivers, and repeated painful experiences during early life have been associated with negative physiological, behavioral, and neurodevelopmental outcomes. Current guidelines from pediatric and neonatal organizations emphasize the importance of minimizing pain through safe, effective, and feasible strategies. Non-pharmacological methods such as white noise and vibration-cold devices (e.g., Buzzy) are increasingly recommended because they are simple, inexpensive, and easily integrated into routine clinical workflows. However, there is limited evidence comparing the effectiveness of these two methods specifically during infant vaccination.
This study is designed as a single-center, randomized controlled, experimental trial aimed at evaluating and comparing the effects of white noise and the Buzzy device on pain experienced by infants during vaccination. The study will be conducted at the Büyükçekmece Central Family Health Center in Istanbul, Türkiye, between October 2025 and October 2026. The target population includes healthy infants aged 0 to 6 months who are scheduled to receive the routine hexavalent vaccine (diphtheria, acellular pertussis, tetanus, inactivated polio, Haemophilus influenzae type B, and hepatitis B).
A total of 108 infants will be included based on a priori power analysis performed using G*Power software, assuming an alpha level of 0.05, a power of 95%, and an anticipated large effect size. To account for potential dropout or exclusions, 36 infants will be assigned to each of the three study groups: (1) White Noise Group, (2) Buzzy Device Group, and (3) Control Group. Randomization will be conducted by an independent statistician using stratified randomization based on infant age (2, 4, or 6 months) and sex to ensure balanced distribution across groups. The study will use a single-blind design in which the observer assessing pain scores is blinded to group assignment.
In the White Noise Group, infants will listen to white noise beginning approximately 1 to 2 minutes before the vaccination and continuing throughout the procedure. The device will be placed safely within hearing distance of the infant. In the Buzzy Group, the Buzzy device-providing combined vibration and cold stimulation-will be applied approximately 3 cm above the injection site starting 60 seconds before the injection and will remain active until the end of the vaccination. In the Control Group, infants will receive the standard vaccination procedure without additional intervention. All vaccinations will be performed by the same trained nurse to ensure procedural consistency. A parent will remain present for the infant's comfort and to assist in observing behavioral cues.
Pain will be evaluated using the validated FLACC Pain Assessment Scale (Face, Legs, Activity, Cry, Consolability), a widely used behavioral tool suitable for infants and young children. During the vaccination, pain scores will be independently assessed by both a blinded observer (trained research nurse) and the parent. The total FLACC score ranges from 0 (no pain) to 10 (severe pain). Higher scores indicate greater pain. Sociodemographic data for infants and parents will also be collected using a structured introductory information form developed from relevant literature.
Data analysis will be performed using SPSS software. Normality of continuous variables will be assessed using the Kolmogorov-Smirnov test. Depending on the distribution, appropriate parametric or non-parametric tests will be applied. Between-group comparisons for FLACC scores will be conducted using ANOVA or the Kruskal-Wallis test, with post hoc analyses performed where necessary. Descriptive statistics (mean, median, standard deviation, and percentages) will be used to summarize sample characteristics. A significance level of p < 0.05 will be used for all statistical tests.
The primary objective of this study is to determine whether white noise or the Buzzy device is more effective in reducing pain during infant vaccination compared with standard care. Secondary objectives include comparing the relative effectiveness of the two methods against each other and evaluating factors that may influence pain perception, such as infant age and sex. By generating evidence on the comparative effectiveness of these widely available non-pharmacological interventions, this study aims to support the development of best practices for infant pain management in primary care settings.
The findings may inform clinical guidelines, enhance nurse-led pain management strategies, and contribute to the broader adoption of evidence-based, non-pharmacological methods in pediatric care. If shown to be effective, these techniques may be recommended for routine use during infant vaccinations to improve comfort, reduce distress, and support family-centered care. The study also seeks to raise awareness among healthcare providers and caregivers regarding simple, safe, and practical ways to reduce procedural pain in infants.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| White Noise Group | Experimental | Other: Standard Care (in control arm)Infants in this group will listen to white noise beginning approximately 1-2 minutes before the vaccination and continuing throughout the injection procedure. The white noise device will be placed safely within hearing distance of the infant. Pain will be assessed using the FLACC Pain Assessment Scale by a blinded observer and a parent. |
| Buzzy Device Group | Experimental | Other: Standard Care (in control arm)Infants in this group will receive vibration and cold stimulation using the Buzzy device. The device will be placed about 3 cm above the injection site 60 seconds before vaccination and will remain active until the procedure is completed. Pain will be assessed using the FLACC Pain Assessment Scale by a blinded observer and a parent. |
| Control Group | Experimental | Other: Standard Care (in control arm)Infants in this group will receive routine vaccination following standard clinical practice with no additional non-pharmacological intervention. Pain will be assessed using the FLACC Pain Assessment Scale by a blinded observer and a parent. |
Who may qualify
- Ages
- 2 to 6 months
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (11 listed)
- Infants aged 2 to 6 months
- Receiving routine hexavalent vaccination
- Born at term (≥37 weeks gestation)
- Medically stable at the time of vaccination
- Parent or legal guardian able to provide written informed consent Exclusion Criteria
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard Care (in control arm)White noise will be played 1-2 minutes before vaccination and continued throughout the procedure. The device will be placed within safe hearing distance of the infant. This auditory distraction method is intended to reduce procedural pain. No physical stimulation will be applied. The Buzzy device will be placed about 3 cm above the injection site 60 seconds before vaccination and kept active until the procedure ends. The device provides vibration and cold stimulation to decrease pain by activating competing sensory pathways. Infants in the control arm will receive routine vaccination with no additional intervention. No white noise, vibration, or cold stimulation will be used. Pain will be assessed according to standard observation procedures. | Other | Buzzy Device Group, Control Group, White Noise Group |
Primary outcome
FLACC Pain Score During Vaccination
Time frame: Periprocedural (during vaccination)
Pain during vaccination will be assessed using the FLACC Pain Assessment Scale (Face, Legs, Activity, Cry, Consolability). Scores range from 0 to 10, with higher scores indicating greater pain. Pain will be independently evaluated for each infant by a blinded observer and a parent.
1 secondary outcome
Agreement Between Parent and Observer FLACC Pain Scores
Time frame: Immediately after vaccination
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to ethical and confidentiality considerations.
Related trials for Infant Pain Management
Recruiting
The Effect of Breast Milk, 10% and 20% Dextrose on Pain and Physiological Variables During Heel Puncture in Infants
Newborn Care, Pain Management
Active, not recruiting
RELIEF-pathway in Patients With Upper Abdominal Pain
Abdominal Pain, Gallstone; Colic
Not yet recruitingPhase 2/3
Dexmedetomidine for Invasive Ventilation In the NEOnate
Invasive Ventilation, Infant Pain
Recruiting
Evaluation of Paro, a Therapeutic Assistance Robot in Analgesic Management During the Placement of a Peripheral Intravenous Line in Infants and Children.
Pain Management
RecruitingObservational study
Rebooting Infant Pain Care: Using Machine Learning and Skin-to-Skin Contact to Exponentially Improve Neonatal Intensive Care Unit Practice
Acute Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of Infant Pain Management, run by Istanbul Arel University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
FLACC Pain Score During Vaccination (time frame: Periprocedural (during vaccination)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.